Compare Stocks: RFL, EYPT, BIOA, and ACB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACB Aurora Cannabis	$4.17 -2.8%	$3.91	$2.56 ▼ $6.36	$274.05M	0.63	1.13 million shs	1.19 million shs
BIOA BioAge Labs	$5.42 -2.7%	$8.75	$5.04 ▼ $25.95	$248.78M	1.08	714,119 shs	614,836 shs
EYPT Eyepoint Pharmaceuticals	$3.01 -2.0%	$5.62	$2.93 ▼ $19.11	$259.49M	1.67	2.14 million shs	3.16 million shs
RFL Rafael	$1.42 -4.8%	$2.03	$1.12 ▼ $3.96	$73.79M	0.35	139,324 shs	47,922 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACB Aurora Cannabis	-1.38%	-6.54%	+14.71%	+61.28%	-20.56%
BIOA BioAge Labs	-6.23%	-11.45%	-34.39%	-75.46%	+1.27%
EYPT Eyepoint Pharmaceuticals	-7.53%	-3.15%	-27.42%	-77.83%	-76.99%
RFL Rafael	-2.63%	-0.74%	-35.84%	-36.66%	+10.62%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACB Aurora Cannabis	$4.17 -2.8%	$3.91	$2.56 ▼ $6.36	$274.05M	0.63	1.13 million shs	1.19 million shs
BIOA BioAge Labs	$5.42 -2.7%	$8.75	$5.04 ▼ $25.95	$248.78M	1.08	714,119 shs	614,836 shs
EYPT Eyepoint Pharmaceuticals	$3.01 -2.0%	$5.62	$2.93 ▼ $19.11	$259.49M	1.67	2.14 million shs	3.16 million shs
RFL Rafael	$1.42 -4.8%	$2.03	$1.12 ▼ $3.96	$73.79M	0.35	139,324 shs	47,922 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACB Aurora Cannabis	-1.38%	-6.54%	+14.71%	+61.28%	-20.56%
BIOA BioAge Labs	-6.23%	-11.45%	-34.39%	-75.46%	+1.27%
EYPT Eyepoint Pharmaceuticals	-7.53%	-3.15%	-27.42%	-77.83%	-76.99%
RFL Rafael	-2.63%	-0.74%	-35.84%	-36.66%	+10.62%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACB Aurora Cannabis	2.00	Hold	N/A	N/A
BIOA BioAge Labs	2.63	Moderate Buy	$33.00	508.86% Upside
EYPT Eyepoint Pharmaceuticals	2.27	Hold	$25.70	753.82% Upside
RFL Rafael	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest RFL, EYPT, BIOA, and ACB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/11/2026	BIOA BioAge Labs	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Neutral	$8.00
10/11/2026	BIOA BioAge Labs	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold
10/8/2026	BIOA BioAge Labs	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
10/5/2026	ACB Aurora Cannabis	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Strong-Buy ➝ Hold
10/2/2026	ACB Aurora Cannabis	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
9/16/2026	ACB Aurora Cannabis	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
9/9/2026	BIOA BioAge Labs	Roth Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$25.00
9/8/2026	BIOA BioAge Labs	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$40.00
9/2/2026	EYPT Eyepoint Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Buy ➝ Hold	$20.00 ➝ $4.00
9/1/2026	EYPT Eyepoint Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
8/26/2026	ACB Aurora Cannabis	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 10/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACB Aurora Cannabis	$247.82M	1.11	$0.67 per share	6.20	$6.27 per share	0.67
BIOA BioAge Labs	$8.99M	27.67	N/A	N/A	$7.59 per share	0.71
EYPT Eyepoint Pharmaceuticals	$31.37M	8.27	N/A	N/A	$3.70 per share	0.81
RFL Rafael	$920K	80.20	N/A	N/A	$1.91 per share	0.74

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACB Aurora Cannabis	-$88.13M	-$1.41	N/A	69.50	N/A	-32.26%	4.37%	3.45%	11/4/2026 (Estimated)
BIOA BioAge Labs	-$80.61M	-$2.38	N/A	N/A	N/A	-912.26%	-28.99%	-27.09%	N/A
EYPT Eyepoint Pharmaceuticals	-$231.96M	-$3.74	N/A	N/A	N/A	-10,994.73%	-135.81%	-108.35%	11/4/2026 (Estimated)
RFL Rafael	-$30.52M	-$0.68	N/A	N/A	N/A	-3,321.74%	-41.27%	-35.32%	10/28/2026 (Estimated)

Latest RFL, EYPT, BIOA, and ACB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/4/2026	Q2 2027	ACB Aurora Cannabis	-$0.03	N/A	N/A	N/A	$50.68 million	N/A
11/4/2026	Q3 2026	EYPT Eyepoint Pharmaceuticals	-$0.9052	N/A	N/A	N/A	$0.23 million	N/A
8/5/2026	Q1 2027	ACB Aurora Cannabis	-$0.13	$0.04	+$0.17	-$0.05	$47.45 million	$47.62 million
8/5/2026	Q2 2026	BIOA BioAge Labs	-$0.65	-$0.58	+$0.07	-$0.58	N/A	$2.45 million
8/5/2026	Q2 2026	EYPT Eyepoint Pharmaceuticals	-$1.01	-$1.09	-$0.08	-$0.2720	$0.45 million	$0.51 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACB Aurora Cannabis	N/A	N/A	N/A	N/A	N/A
BIOA BioAge Labs	N/A	N/A	N/A	N/A	N/A
EYPT Eyepoint Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RFL Rafael	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACB Aurora Cannabis	0.03	5.36	2.80
BIOA BioAge Labs	N/A	17.19	17.19
EYPT Eyepoint Pharmaceuticals	N/A	4.50	4.46
RFL Rafael	N/A	3.16	3.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACB Aurora Cannabis	47.63%
BIOA BioAge Labs	N/A
EYPT Eyepoint Pharmaceuticals	99.41%
RFL Rafael	11.30%

Insider Ownership

Company	Insider Ownership
ACB Aurora Cannabis	0.01%
BIOA BioAge Labs	17.55%
EYPT Eyepoint Pharmaceuticals	5.13%
RFL Rafael	32.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACB Aurora Cannabis	1,028	65.72 million	65.72 million	Optionable
BIOA BioAge Labs	62	45.90 million	37.84 million	N/A
EYPT Eyepoint Pharmaceuticals	214	86.21 million	81.79 million	Optionable
RFL Rafael	23	52.00 million	34.89 million	Optionable

RFL, EYPT, BIOA, and ACB Headlines

Recent News About These Companies

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc. - RFL

October 13 at 5:29 PM | globenewswire.com

Reviewing Rafael (NYSE:RFL) & vTv Therapeutics (NASDAQ:VTVT)

October 12 at 8:14 AM | americanbankingnews.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc. - RFL

October 8, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc. - RFL

October 6, 2026 | globenewswire.com

Rafael’s Trappsol Cyclo Misses Primary Endpoint, Targets 2026 FDA Filing

October 4, 2026 | marketbeat.com

Rafael Holdings: A Coin Flip With A Second Binary Attached - Hold

October 1, 2026 | seekingalpha.com

Rafael Holdings shares fall 25% after Trappsol Cyclo phase 3 trial misses primary endpoint

September 30, 2026 | msn.com

Rafael Holdings stock tumbles 25% as drug trial misses goal

September 30, 2026 | ca.finance.yahoo.com

Rafael Holdings, Inc. (RFL) Discusses Topline Results of Phase III TransportNPC Study of Trappsol Cyclo in Niemann-Pick Disease Type C Transcript

September 30, 2026 | seekingalpha.com

Rafael Reports Phase 3 Trappsol Cyclo Data In NPC

September 30, 2026 | rttnews.com

Rafael's Trappsol Cyclo Shows Significant Benefit In NPC Prespecified Analysis

September 30, 2026 | rttnews.com

Rafael Holdings Announces Topline Results from the Pivotal Phase 3 TransportNPC™ Study of Trappsol® Cyclo™ in Niemann-Pick Disease Type C (NPC)

September 30, 2026 | globenewswire.com

Rafael Holdings Inc Share Price (RFL.US)

July 15, 2026 | lse.co.uk

Rafael Holdings Insider Trading Activity | NYSE:RFL | Benzinga

July 2, 2026 | benzinga.com

Rafael Holdings: The Second Half Of Calendar 2026 Could Define This Company Forever

June 29, 2026 | seekingalpha.com

Rafael Holdings (NYSE:RFL) Stock, Short Interest Report

June 25, 2026 | benzinga.com

Rafael Holdings (NYSE: RFL) - Share Price and Research

June 25, 2026 | intelligentinvestor.com.auI

Rafael B Stock Price History

June 11, 2026 | investing.com

Rafael Holdings, Inc. Reports Q3 Fiscal 2026 Financial Results and Progress on Phase 3 TransportNPC™ Trial

June 11, 2026 | quiverquant.comQ

Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results

June 11, 2026 | globenewswire.com

Rafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick ...

June 10, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

RFL, EYPT, BIOA, and ACB Company Descriptions

Aurora Cannabis NASDAQ:ACB

$4.17 -0.12 (-2.80%)

Closing price 04:00 PM Eastern

Extended Trading

$4.16 -0.01 (-0.36%)

As of 05:33 PM Eastern

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

BioAge Labs NASDAQ:BIOA

$5.42 -0.15 (-2.69%)

Closing price 04:00 PM Eastern

Extended Trading

$5.42 0.00 (0.00%)

As of 04:10 PM Eastern

We are a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights into molecular changes that drive aging. Our primary focus is metabolic disease, one of the greatest global healthcare challenges. Azelaprag, our lead product candidate, is an orally available small molecule that has been well-tolerated in 265 individuals across eight Phase 1 clinical trials. In preclinical obesity models, azelaprag demonstrated the ability to more than double the weight loss induced by a glucagon-like-peptide-1 receptor (GLP-1R) agonist while also restoring healthy body composition and improving muscle function. These preclinical results are supported by our Phase 1b clinical trial in older adults on bed rest where we observed decreased muscle atrophy, preservation of muscle quality and improved metabolism in subjects treated with azelaprag over a 10-day period. We plan to assess azelaprag’s potential to drive significant improvements in weight loss when combined with a GLP-1R agonist in two Phase 2 clinical trials. While the results of these preclinical studies and early clinical trials have demonstrated the potential use of azelaprag for the treatment of metabolic disease, they may not be predictive of the results of later-stage clinical trials. The ongoing STRIDES clinical trial will assess azelaprag in combination with tirzepatide, marketed as Zepbound® by Eli Lilly and Company (Lilly), with topline results anticipated in the third quarter of 2025. The second Phase 2 clinical trial will assess azelaprag in combination with semaglutide, marketed as Wegovy® by Novo Nordisk, with initiation expected in the first half of 2025 and topline results expected in the second half of 2026. We believe these trials will directly support our ultimate therapeutic goal of developing an all-oral combination product for obesity. We also intend to initiate an insulin sensitivity proof-of-concept trial of azelaprag monotherapy in the first half of 2025 to support potential indication expansion. We expect to report topline results from this proof-of-concept trial in the second half of 2025. We are also developing orally available small molecule brain-penetrant NLRP3 inhibitors for the treatment of diseases driven by neuroinflammation. We anticipate submitting an Investigational New Drug application (IND) for an NLRP3 inhibitor in the second half of 2025 and, if cleared, initiating a Phase 1 clinical trial in the first half of 2026. Our approach: Targeting human aging biology to treat chronic metabolic diseases The burden of many serious and chronic diseases—including cardiovascular disease and diabetes—increases with age. However, there is substantial natural variation in the human population, resulting in a broad range of aging trajectories and outcomes, with some people experiencing much longer lifespans as well as delayed disease onset. We created our company to identify biological pathways associated with longer, healthier human lifespans and to develop pharmaceutical products that can modulate these pathways with the intent to prevent and reverse specific diseases, focusing on metabolic diseases. --- Our approach starts with human data. We examine the impact of the molecular changes that happen naturally as people age and study how these changes drive both functional decline (e.g., loss of muscle strength) and disease risk (e.g., obesity, insulin resistance, dyslipidemia, hypertension). To develop new insights into the biological drivers of aging, we have generated proprietary longitudinal human datasets based on exclusive access to a unique resource: serial biobanked human samples coupled with health records and functional measurements collected for up to 50 years, capturing individual aging trajectories measured over several decades. We analyze these samples using state-of-the-artmolecular profiling technologies, measuring thousands of biologically relevant molecules, and then apply computational tools to the resulting data to extract potential drivers of a long and healthy lifespan. --- We have selected chronic metabolic diseases as our primary focus within age related chronic diseases, given their high prevalence and resulting potential for impact on population health. Chronic metabolic diseases represent some of the largest addressable therapeutics markets. Through our approach, we expect to target outsized commercial opportunities, initially within the obesity and diabetes landscape. For instance, according to third-party estimates, the global market for GLP-1R agonists, including those used to treat diabetes, is expected to grow to $150 billion by 2031. We were incorporated under the laws of the State of Delaware on April 1, 2015, under the name BioAge Labs, Inc. Our principal executive offices are located at 1445A South 50th Street, Richmond, California.

Eyepoint Pharmaceuticals NASDAQ:EYPT

$3.01 -0.06 (-1.95%)

Closing price 04:00 PM Eastern

Extended Trading

$3.00 0.00 (-0.17%)

As of 05:34 PM Eastern

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Rafael NYSE:RFL

$1.42 -0.07 (-4.77%)

Closing price 03:59 PM Eastern

Extended Trading

$1.41 -0.01 (-0.63%)

As of 04:10 PM Eastern

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RFL, EYPT, BIOA, and ACB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RFL, EYPT, BIOA, and ACB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RFL, EYPT, BIOA, and ACB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RFL, EYPT, BIOA, and ACB Company Descriptions

Aurora Cannabis NASDAQ:ACB

BioAge Labs NASDAQ:BIOA

Eyepoint Pharmaceuticals NASDAQ:EYPT

Rafael NYSE:RFL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RFL, EYPT, BIOA, and ACB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RFL, EYPT, BIOA, and ACB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RFL, EYPT, BIOA, and ACB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RFL, EYPT, BIOA, and ACB Company Descriptions

Aurora Cannabis NASDAQ:ACB

BioAge Labs NASDAQ:BIOA

Eyepoint Pharmaceuticals NASDAQ:EYPT

Rafael NYSE:RFL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools